 Dyadic International Inc NASDAQ: DYAI and Sorrento Therapeutics Inc NASDAQ: SRNE have announced a binding term sheet for a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadics lead COVID-19 vaccine candidate, DYAI-100. DYAI-100 is produced using Dyadics proprietary and patented C1-cell protein production platform. 